|Day Low/High||252.51 / 259.10|
|52 Wk Low/High||176.36 / 292.75|
Let's take a deep dive into the First Trust Long/Short Equity exchange-traded fund, which looks to make gains on shorted stocks as well as additional profit from levered positions.
Here's my take on several 'innovation' funds -- and which one might be the best bet.
The stock has broken a long-term downtrend, which gets my attention.
The beaten-down biotech sector had one of the best weeks in a year. Are these names still oversold?
These recently downgraded names are displaying both quantitative and technical deterioration.
Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.
While it's tempting to take on a long-side trade here, I don't see a good reason.
Let's not kid ourselves that there is any longer some kind of relationship between price and value. Or fact and truth.
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
The short-term charts of VRTX suggest that this stock can see further sideways to lower price action in the weeks ahead.
Investors should continue to hold their positions on VRTX.
There was a mild increase in trading volume at the New York Stock Exchange, but it was a rotational shift.
Oil isn't really worthless and Amazon isn't the only retailer that will survive, but we are in a mixed up market thanks to Covid-19.
The pace of the rally in the drugmaker's shares is slowing, which is one reason to keep an eye on its stock.
VRTX is poised for further upside price gains.
The indices are within striking distance of the July highs after moving into position for a possible strong finish to the year.
Straying from these names could land you in quicksand as the 4th quarter begins.
It is all about perception, and here are strong names to pick up on market weakness.
The potential of these setups on the weekly chart is rather good.
After pharmaceutical company breaks out, charts suggest now is the time to go back in.
Look no further than the top 10 winners in the S&P 500 and you will see just what I mean.